BDBM324297 5-(tert-butyl)-N-(3-(2-((1-methyl-H-pyrazol-4-yl)amino)pyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[c]pyridin-9-yl)-1,3,4-oxadiazole-2-carboxamide ::US10189829, Compound 40::US10189829, Compound 41::US10227341, Compound 40::US10961237, Compound 41
SMILES: Cn1cc(Nc2nccc(n2)-c2cc3CCCCC(NC(=O)c4nnc(o4)C(C)(C)C)c3cn2)cn1
InChI Key: InChIKey=IBADWWZLDGKQST-UHFFFAOYSA-N
Data: 5 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM324297 (5-(tert-butyl)-N-(3-(2-((1-methyl-H-pyrazol-4-yl)a...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1 | n/a | n/a | n/a | n/a | n/a | n/a |
BIOGEN MA INC. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US10189829 (2019) BindingDB Entry DOI: 10.7270/Q2V69MP8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM324297 (5-(tert-butyl)-N-(3-(2-((1-methyl-H-pyrazol-4-yl)a...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1 | n/a | n/a | n/a | n/a | n/a | n/a |
BIOGEN MA INC. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US10189829 (2019) BindingDB Entry DOI: 10.7270/Q2V69MP8 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM324297 (5-(tert-butyl)-N-(3-(2-((1-methyl-H-pyrazol-4-yl)a...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1 | n/a | n/a | n/a | n/a | n/a | n/a |
BIOGEN MA INC. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US10961237 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM324297 (5-(tert-butyl)-N-(3-(2-((1-methyl-H-pyrazol-4-yl)a...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1 | n/a | n/a | n/a | n/a | n/a | n/a |
BIOGEN MA INC. US Patent | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | US Patent US10961237 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM324297 (5-(tert-butyl)-N-(3-(2-((1-methyl-H-pyrazol-4-yl)a...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 505 | n/a | n/a | n/a | n/a | n/a | n/a |
Neuroscience | Assay Description The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a... | J Med Chem 51: 1730-9 (2008) BindingDB Entry DOI: 10.7270/Q25M681D | |||||||||||
More data for this Ligand-Target Pair |